e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Remon Jordi, Gorham Julie, Besse Benjamin, Sculier Jean-Paul
Source:
Eur Respir J 2015; 46: 1548-1550
Journal Issue:
December
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Remon Jordi, Gorham Julie, Besse Benjamin, Sculier Jean-Paul. Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?. Eur Respir J 2015; 46: 1548-1550
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
Soluble non-invasive markers in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005
Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival
Source: Eur Respir J 2011; 37: 617-623
Year: 2011
Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 482s
Year: 2005
CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
Year: 2005
Serum hepcidin and iron are associated with non-small cell lung cancer stage
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer?
Source: Eur Respir J 2001; 18: Suppl. 33, 232s
Year: 2001
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
New treatment options for nonsmall cell lung cancer and small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005
T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017
Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 770s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept